Unique ID issued by UMIN | UMIN000007792 |
---|---|
Receipt number | R000009184 |
Scientific Title | The analysis of monocyte characters on Mild Electrical stimulation with hyperThermia treatment in metabolic syndrome or type 2 diabetes. |
Date of disclosure of the study information | 2012/04/20 |
Last modified on | 2015/04/20 09:20:06 |
The analysis of monocyte characters on Mild Electrical stimulation with hyperThermia treatment in metabolic syndrome or type 2 diabetes.
The analysis of monocyte characters on MET treatment in MS or T2DM
The analysis of monocyte characters on Mild Electrical stimulation with hyperThermia treatment in metabolic syndrome or type 2 diabetes.
The analysis of monocyte characters on MET treatment in MS or T2DM
Japan |
Metabolic syndrome
Type 2 diabetes mellitus
Endocrinology and Metabolism |
Others
NO
Mild Electrical stimulation with hyperThermia (MET) improves insulin resistance and glucose homeostasis.
This study aims to identify the molecular mechanisms to improve metabolic profiles on MET, especially in circulating monocytes.
Efficacy
The expression of CRP, IL-6, NF-kB, TNF-a, HSP72 in monocytes.
Interventional
Cross-over
Randomized
Individual
Open -but assessor(s) are blinded
No treatment
NO
2
Treatment
Device,equipment |
MET treatment (1.4 V/cm, 0.1ms, 55 pps, 42 degrees for 60min), 4 times/week for 4weeks. Then 4weeks of no treatment.
First, 4 weeks of no treatment. Then, MET treatment (1.4 V/cm, 0.1ms, 55 pps, 42 degrees for 60min), 4 times/week for 4weeks.
40 | years-old | <= |
65 | years-old | >= |
Male
Metabolic syndrome (MS)
Abdominal obesity, given as waist circumference
greater than 85 cm with meets 2 criteria in 3 shown below,
i)Triglycerides: greater than or equal to 150 mg/dL and/or HDL cholesterol: less than 40 mg/dL
ii)Systolic Blood pressure: greater than or equal to130 mmHg and/or Diastolic blood pressure: greater than or equal to 85 mmHg
iii)Fasting blood glucose: greater than or equal to 110 mg/dL
Type 2 diabetes mellitus (T2DM)
i)Abdominal obesity, given as waist circumference
greater than 85 cm
ii)HbA1c more than 6.9%, less than 9.5% (NGSP)
i) Past history or current medication of myocardial infarction, angina, apoplexy and arteriosclerosis obliterans.
ii)Severe wound, infections, pre- or post-operation.
iii)Severe liver dysfunction (GOT and/or GPT: greater than 100U).
iv)Chronic heart failure, familial dyslipidemia.
v)Severe diabetic complications.
vi)HbA1c : greater than or equal to 6.9%. (only in MS)
vii)Pacemaker carrier.
20
1st name | |
Middle name | |
Last name | Eiichi Araki |
Kumamoto University, Faculty of Life Sciences
Metabolic Medicine
1-1-1 Honjo, Kumamoto
096-373-5169
earaki@gpo.kumamoto-u.ac.jp
1st name | |
Middle name | |
Last name | Tatsuya Kondo |
Kumamoto University, Faculty of Life Sciences
Metabolic Medicine
1-1-1 Honjo, Chuo-ku, Kumamoto
096-373-5169
t-kondo@gpo.kumamoto-u.ac.jp
Kumamoto University, Faculty of Life Sciences, Metabolic Medicine
Kumamoto University, Faculty of Life Sciences, Metabolic Medicine
Self funding
NO
2012 | Year | 04 | Month | 20 | Day |
Published
http://www.ebiomedicine.com/
Upon HS+MES treatment, glucose homeostasis and inflammatory cytokine levels were significantly improved in MS or T2DM patients.
In circulating monocytes, HS+MES reduced inflammatory signal molecules as well.
Completed
2012 | Year | 04 | Month | 17 | Day |
2012 | Year | 05 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
2014 | Year | 06 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2012 | Year | 04 | Month | 20 | Day |
2015 | Year | 04 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009184
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |